Abstract
Purpose
Diffuse gliomas are the most common primary malignant brain tumors in adults. Many studies analyzed their epidemiology, such as the incidence and mortality. Moreover, the identification of their risk factors is still controversial and to date we have only a few accepted and confirmed risk factors. In the last few years, many molecular markers have been analyzed and correlated to the prognosis of gliomas.
We performed a review aiming to collect and clarify data on epidemiology, risk factors and prognostic factors regarding glioma patients.
Methods
We performed a comprehensive literature review of research studies focusing on epidemiology of gliomas and their risk factors. At the same time, we collected studies analyzing the most important and validated prognostic factors in glioma patients.
Results
Glioblastoma represents the most common primary malignant brain tumor with an incidence rate of 3.23 per 100,000 population. Diffuse astrocytoma and oligodendroglioma tend to peak in young adults with a median age of 46 and 43 years, respectively). Overall, the incidence rate of gliomas is higher in male patients than in females. Rates of overall survival vary widely, ranging from 5 year survival rates of 94.7% for pilocytic astrocytoma to 6.8% for glioblastoma. About 5% of gliomas can be classified as familial and associated with hereditary syndromes, such as the Li-Fraumeni, the Turcot and neurofibromatosis. Ionizing radiation remains the only ascertained environmental risk factor associated with glioma. In addition to the clinical characteristics, such as the age, performance status and the extent of resection, also mutational status of some genes such as IDH, TERT, CDKN2A and the MGMT methylation status can be correlated with the glioma patient survival.
Conclusions
Gliomas represent rare tumors and can be defined as a heterogenous group of primitive brain tumors. In recent years, new data emerged regarding the etiology of these tumors as well as the knowledge of new prognostic factors.
Similar content being viewed by others
References
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol 22(12 Supp 2):iv1–iv96. https://doi.org/10.1093/neuonc/noaa200
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
Patil N, Kelly ME, Yeboa DN et al (2021) Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000–2017. Neuro Oncol 23(6):990–998. https://doi.org/10.1093/neuonc/noaa295
Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N et al (2018) Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and European society for pediatric oncology DIPG registries. J Clin Oncol 36(19):1963–1972. https://doi.org/10.1200/JCO.2017.75.9308
Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS (2017) Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro Oncol 19(11):1553–1564. https://doi.org/10.1093/neuonc/nox091
Girardi F, Rous B, Stiller CA et al (2021) The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000–2014: a global, population-based study (CONCORD-3). Neuro Oncol 23(10):1765–1776. https://doi.org/10.1093/neuonc/noab067
Nakamura H, Makino K, Yano S, Kuratsu JI (2011) Kumamoto brain tumor research group epidemiological study of primary intracranial tumors: a regional survey in kumamoto prefecture in southern Japan–20-year study. Int J Clin Oncol 16(4):314–321. https://doi.org/10.1007/s10147-010-0178-y
Ostrom QT, Egan KM, Nabors LB et al (2020) Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. Int J Cancer 146(3):739–748. https://doi.org/10.1002/ijc.32318
Lin D, Wang M, Chen Y et al (2021) Trends in intracranial glioma incidence and mortality in the United States, 1975–2018. Front Oncol 11:748061. https://doi.org/10.3389/fonc.2021.748061
Wrensch M, Lee M, Miike R et al (1997) Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol 145(7):581–593. https://doi.org/10.1093/oxfordjournals.aje.a009154
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
Ostrom QT, Fahmideh MA, Cote DJ et al (2019) Risk factors for childhood and adult primary brain tumors. Neuro Oncol 21(11):1357–1375. https://doi.org/10.1093/neuonc/noz123
Kinnersley B, Mitchell JS, Gousias K et al (2015) Quantifying the heritability of glioma using genome-wide complex trait analysis. Sci Rep 5:17267. https://doi.org/10.1038/srep17267
Rice T, Lachance DH, Molinaro AM et al (2016) Understanding inherited genetic risk of adult glioma - a review. Neurooncol Pract 3(1):10–16. https://doi.org/10.1093/nop/npv026
Howell AE, Zheng J, Haycock PC et al (2018) Use of mendelian randomization for identifying risk factors for brain tumors. Front Genet 9:525. https://doi.org/10.3389/fgene.2018.00525
Francis SS, Ostrom QT, Cote DJ, Smith TR, Claus E, Barnholtz-Sloan JS (2022) The epidemiology of central nervous system tumors. Hematol Oncol Clin North Am 36(1):23–42. https://doi.org/10.1016/j.hoc.2021.08.012
Khattab A, Monga DK. (2021) Turcot Syndrome. In: StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK534782/. Accessed 6 Jan 2022
Braganza MZ, Kitahara CM, Berrington de González A, Inskip PD, Johnson KJ, Rajaraman P (2012) Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 14(11):1316–1324. https://doi.org/10.1093/neuonc/nos208
Davis F, Il’yasova D, Rankin K, McCarthy B, Bigner DD (2011) Medical diagnostic radiation exposures and risk of gliomas. Radiat Res 175(6):790–796. https://doi.org/10.1667/RR2186.1
Neglia JP, Robison LL, Stovall M et al (2006) New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 98(21):1528–1537. https://doi.org/10.1093/jnci/djj411
Inskip PD, Sigurdson AJ, Veiga L et al (2016) Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys 94(4):800–807. https://doi.org/10.1016/j.ijrobp.2015.11.046
Sheppard JP, Nguyen T, Alkhalid Y, Beckett JS, Salamon N, Yang I (2018) Risk of brain tumor induction from pediatric head CT procedures: a systematic literature review. Brain Tumor Res Treat 6(1):1–7. https://doi.org/10.14791/btrt.2018.6.e4
INTERPHONE Study Group (2010) Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol 39(3):675–694. https://doi.org/10.1093/ije/dyq079
Benson VS, Pirie K, Schüz J et al (2013) Mobile phone use and risk of brain neoplasms and other cancers: prospective study. Int J Epidemiol 42(3):792–802. https://doi.org/10.1093/ije/dyt072
Frei P, Poulsen AH, Johansen C, Olsen JH, Steding-Jessen M, Schüz J (2011) Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ 343:d6387. https://doi.org/10.1136/bmj.d6387
Porter AB, Lachance DH, Johnson DR (2015) Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control 26(2):179–185. https://doi.org/10.1007/s10552-014-0496-x
Demers PA, Vaughan TL, Schommer RR (1991) Occupation, socioeconomic status, and brain tumor mortality: a death certificate-based case-control study. J Occup Med 33(9):1001–1006
Plascak JJ, Fisher JL (2013) Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS ONE 8(4):e60910. https://doi.org/10.1371/journal.pone.0060910
Khanolkar AR, Ljung R, Talbäck M et al (2016) Socioeconomic position and the risk of brain tumour: a Swedish national population-based cohort study. J Epidemiol Community Health 70(12):1222–1228. https://doi.org/10.1136/jech-2015-207002
Cote DJ, Ostrom QT, Gittleman H et al (2019) Glioma incidence and survival variations by county-level socioeconomic measures. Cancer 125(19):3390–3400. https://doi.org/10.1002/cncr.32328
Dlamini Z, Alaouna M, Mbatha S et al (2021) Genetic drivers of head and neck squamous cell carcinoma: aberrant splicing events, mutational burden, HPV infection and future targets. Genes (Basel) 12(3):422. https://doi.org/10.3390/genes12030422
Araldi RP, Sant’Ana TA, Módolo DG, et al (2018) The human papillomavirus (HPV)-related cancer biology: an overview. Biomed Pharmacother 106:1537–1556. https://doi.org/10.1016/j.biopha.2018.06.149
Neves AM, Thompson G, Carvalheira J et al (2008) Detection and quantitative analysis of human herpesvirus in pilocytic astrocytoma. Brain Res 1221:108–114. https://doi.org/10.1016/j.brainres.2008.05.009
Garcia-Martinez A, Alenda C, Irles E et al (2017) Lack of cytomegalovirus detection in human glioma. Virol J 14(1):216. https://doi.org/10.1186/s12985-017-0885-3
Wrensch M, Weinberg A, Wiencke J et al (1997) Does prior infection with varicella-zoster virus influence risk of adult glioma? Am J Epidemiol 145(7):594–597. https://doi.org/10.1093/oxfordjournals.aje.a009155
Amirian ES, Scheurer ME, Zhou R et al (2016) History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC). Cancer Med 5(6):1352–1358. https://doi.org/10.1002/cam4.682
Amirian ES, Zhou R, Wrensch MR et al (2016) Approaching a scientific consensus on the association between allergies and glioma risk: a report from the glioma international case-control study. Cancer Epidemiol Biomarkers Prev 25(2):282–290. https://doi.org/10.1158/1055-9965.EPI-15-0847
Linos E, Raine T, Alonso A, Michaud D (2007) Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 99(20):1544–1550. https://doi.org/10.1093/jnci/djm170
Alexandrov LB, Kim J, Haradhvala NJ et al (2020) The repertoire of mutational signatures in human cancer. Nature 578(7793):94–101. https://doi.org/10.1038/s41586-020-1943-3
Claus EB, Cannataro VL, Gaffney SG, Townsend JP (2022) Environmental and sex-specific molecular signatures of glioma causation. Neuro Oncol 24(1):29–36. https://doi.org/10.1093/neuonc/noab103
Hu J, La Vecchia C, Negri E et al (1999) Diet and brain cancer in adults: a case-control study in northeast China. Int J Cancer 81(1):20–23. https://doi.org/10.1002/(sici)1097-0215(19990331)81:1%3c20::aid-ijc4%3e3.0.co;2-2
Giles GG, McNeil JJ, Donnan G et al (1994) Dietary factors and the risk of glioma in adults: results of a case-control study in Melbourne. Australia Int J Cancer 59(3):357–362. https://doi.org/10.1002/ijc.2910590311
Lee M, Wrensch M, Miike R (1997) Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 8(1):13–24. https://doi.org/10.1023/a:1018470802969
Baglietto L, Giles GG, English DR, Karahalios A, Hopper JL, Severi G (2011) Alcohol consumption and risk of glioblastoma; evidence from the melbourne collaborative cohort study. Int J Cancer 128(8):1929–1934. https://doi.org/10.1002/ijc.25770
Braganza MZ, Rajaraman P, Park Y et al (2014) Cigarette smoking, alcohol intake, and risk of glioma in the NIH-AARP diet and health study. Br J Cancer 110(1):242–248. https://doi.org/10.1038/bjc.2013.611
Shao C, Zhao W, Qi Z, He J (2016) Smoking and glioma risk: evidence from a meta-analysis of 25 observational studies. Medicine (Baltimore) 95(2):e2447. https://doi.org/10.1097/MD.0000000000002447
Gu F, Xiao Q, Chu LW et al (2016) Sleep duration and cancer in the NIH-AARP diet and health study cohort. PLoS ONE 11(9):e0161561. https://doi.org/10.1371/journal.pone.0161561
Kuan AS, Green J, Kitahara CM et al (2019) Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA. Neuro Oncol 21(7):944–952. https://doi.org/10.1093/neuonc/noz013
Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22(4):515–523. https://doi.org/10.1093/neuonc/noz200
Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. JCO 20(8):2076–2084. https://doi.org/10.1200/JCO.2002.08.121
van den Bent MJ, Smits M, Kros JM, Chang SM (2017) Diffuse infiltrating oligodendroglioma and astrocytoma. JCO 35(21):2394–2401. https://doi.org/10.1200/JCO.2017.72.6737
Gorlia T, Wu W, Wang M et al (2013) New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. Neuro Oncol 15(11):1568–1579. https://doi.org/10.1093/neuonc/not117
Pallud J, Audureau E, Blonski M et al (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137(Pt 2):449–462. https://doi.org/10.1093/brain/awt345
Chang EF, Smith JS, Chang SM et al (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults: clinical article. J Neurosurg 109(5):817–824. https://doi.org/10.3171/JNS/2008/109/11/0817
Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z
Gorlia T, Delattre JY, Brandes AA et al (2013) New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European organisation for research and treatment of cancer brain tumour group study 26951. Eur J Cancer 49(16):3477–3485. https://doi.org/10.1016/j.ejca.2013.06.039
Molinaro AM, Hervey-Jumper S, Morshed RA et al (2020) Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol 6(4):495–503. https://doi.org/10.1001/jamaoncol.2019.6143
Xia L, Fang C, Chen G, Sun C (2018) Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis. BMC Cancer 18(1):48. https://doi.org/10.1186/s12885-017-3909-x
Jakola AS, Skjulsvik AJ, Myrmel KS et al (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28(8):1942–1948. https://doi.org/10.1093/annonc/mdx230
Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16(1):81–91. https://doi.org/10.1093/neuonc/not159
Bergo E, Lombardi G, Guglieri I, Capovilla E, Pambuku A, Zagonel V (2015) Neurocognitive functions and health-related quality of life in glioblastoma patients: a concise review of the literature. EurJCancerCare (Engl). https://doi.org/10.1111/ecc.12410
Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20(1):110–119
Birzu C, French P, Caccese M et al (2020) Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers (Basel). https://doi.org/10.3390/cancers13010047
Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8):2076–2084. https://doi.org/10.1200/JCO.2002.08.121
Di Stefano AL, Labussiere M, Lombardi G et al (2015) VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab. JNeurooncol 121(3):499–504. https://doi.org/10.1007/s11060-014-1677-x
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 Mutations in gliomas. N Engl J Med. https://doi.org/10.1056/NEJMoa0808710
Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27(25):4150–4154. https://doi.org/10.1200/JCO.2009.21.9832
van den Bent MJ, Tesileanu CMS, Wick W et al (2021) Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053–22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22(6):813–823. https://doi.org/10.1016/S1470-2045(21)00090-5
Franceschi E, De Biase D, Di Nunno V et al (2021) IDH1 Non-canonical mutations and survival in patients with glioma. Diagnostics (Basel) 11(2):342. https://doi.org/10.3390/diagnostics11020342
Tesileanu CMS, Vallentgoed WR, Sanson M et al (2021) Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathol 141(6):945–957. https://doi.org/10.1007/s00401-021-02291-6
Dunn GP, Andronesi OC, Cahill DP (2013) From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus 34(2):E2. https://doi.org/10.3171/2012.12.FOCUS12355
Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343. https://doi.org/10.1200/JCO.2012.43.2674
van den Bent MJ, Brandes AA, Taphoorn MJB et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350. https://doi.org/10.1200/JCO.2012.43.2229
Wick W, Weller M, van den Bent M et al (2014) MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10(7):372–385. https://doi.org/10.1038/nrneurol.2014.100
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091. https://doi.org/10.1200/JCO.2013.49.6968
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331
Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. https://doi.org/10.1016/S1470-2045(12)70265-6
Tesileanu CMS, Gorlia T, Golfinopoulos V, French PJ, van den Bent MJ (2022) MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro Oncol. https://doi.org/10.1093/neuonc/noac014 (Published online January 31)
Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med 377(20):1954–1963. https://doi.org/10.1056/NEJMoa1707358
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Alessia Pellerino, Mario Caccese, Marta Padovan, Giulia Cerretti, Giuseppe Lombardi declare no conflict of interest.
Ethical approval
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pellerino, A., Caccese, M., Padovan, M. et al. Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging 10, 467–475 (2022). https://doi.org/10.1007/s40336-022-00489-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-022-00489-6